Register online | Log in | My Prescrire

Issue contents

• Current issue
• Last 12 issues
• All issues

Topics

• Annual Prescrire Awards
• Advancing healthcare policy
• Positions
• Mediator° - the criminal trial
• Drugs to avoid: 2021 update
• Spotlight

About Prescrire

• Who are we?
• How we work
• AMP: non-profit
• Financing
• "Non merci"
• Where to find us
• About Prescrire International
• Testimonials
• Prescrire events
• A global network

Offers

• Subscribe now
• Solidarity Subscription Rate
• Subscribers: register online
• Prescrire's other products
• Free Special Edition
• Sign up to receive the newsletter

Prescrire's other websites

In Prescrire's Spotlight

Covid-19 vaccine Ad26.CoV2S (by Janssen): as with the other covid-19 vaccines, effective in the short term but unknowns remain  NEWS UPDATE  Covid-19 vaccine Ad26.CoV2S, marketed by the pharmaceutical company Janssen (part of the Johnson & Johnson group), was authorised in the European Union on 11 March 2021. What are the main data available as of mid-March 2021 from clinical trials of covid-19 vaccine Ad26.CoV2S? 23 March 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Covid-19 : Follow Prescrire's independent, evidence-based analysis of the pandemic  COVID-19  Prescrire's editors are publishing an ongoing series of news updates featuring independent analysis of developments related to the covid-19 pandemic. Useful and practical information, to help healthcare professionals gain a clear and balanced view. 1 May 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Rituximab (Mabthera° or other brands) in pemphigus vulgaris: more patients in remission than with other immunosuppressants, lower exposure to corticosteroids, but a risk of cancer FEATURED REVIEW Rituximab was already authorised in the European Union for various inflammatory diseases and various types of cancer. It has now also been authorised for use in moderate to severe pemphigus vulgaris, as add-on therapy with a tapering course of corticosteroid treatment. Full review (5 pages) available for download by subscribers. 1 May 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ In the May issue of Prescrire International: Ciclosporin eye drops (Verkazia°) in severe vernal keratoconjunctivitis FREE DOWNLOAD Eye drops containing ciclosporin at a concentration of 1 mg/ml (Verkazia°) have been authorised in the European Union for severe vernal keratoconjunctivitis in children from 4 years of age and in adolescents. How do Prescrire's editors rate this drug? Full text available for free download. 1 May 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Orphan drugs: amendment needed  Editorial  The European orphan drug regulation needs to be amended, to ensure that it better serves patients' interests, and that the public resources invested benefit public health rather than private interests. 1 May 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Medical cannabis: an experimental programme in France in 2021 The medical use of Cannabis sativa L., also known as hemp or cannabis, appears to be an option in the treatment of certain types of pain, despite its limited evaluation. 1 May 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Baclofen: at moderate doses, an option for some alcohol-dependent patients In addition to medical support, baclofen, at moderate doses of around 30 mg per day, is an option of limited usefulness. 1 May 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Beware of "spin" in clinical trials "Spin doctors" are not doctors in the medical sense, but rather public relations specialists whose job it is to enhance the image of an entity or individual. "Spin" however, in the sense of massaged facts, exists in medicine, where it obstructs the reliable evaluation of new drugs. 1 May 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Revision of the EU's general pharmaceutical legislation in 2022: Prescrire's remarks on the European Commission Roadmap (4/2021)  ADVANCING HEALTHCARE POLICY  Prescrire highlights the need for high standards of assessment for pharmaceuticals, calling for comparative trial data to be included in the marketing authorisation application. Accelerated assessment procedures should be limited to exceptional situations. Prescrire also points out several areas that are missing from the roadmap. 27 April 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Enjoy these features, and more, in our upcoming issues COMING SOON Oral semaglutide • Givosiran in acute hepatic porphyria • Excessive iodine intake during pregnancy • Pre-exposure prophylaxis for HIV... > Subscribe now 1 May 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ "Top Texts of 2020", from the editors of Prescrire International  FREE SPECIAL EDITION  Check out this brand new sampling of texts from Prescrire International, a wholly independent monthly journal written by and for healthcare professionals. Inside, top articles from our "New Products", "Adverse Effects" and "Reviews" sections, plus our annual update of drugs to avoid. > Click here for your free copy 1 March 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Follow Prescrire International on Facebook and Twitter Keep up with the latest from Prescrire's editors, and support our values of independence and quality information, first and foremost in the interest of patients. Click here to > Follow us on Facebook or > Follow us on Twitter 1 November 2020

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Subscribe today for full access to top-quality content from Prescrire International Subscribe now Enjoy access to subscriber-only content available on our website, including every article published in Prescrire International since 1992. Prices for a one-year subscription start at 150 euros (less for students and residents of lower-income countries). 1 November 2020

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Receive the free, monthly "Independent Drug & Healthcare Newsletter" Click here to sign up for the free Newsletter from the editors of the non-profit journal Prescrire International, with highlights of the contents of the latest issue. 1 November 2020

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Drugs to avoid, in the name of better patient care   DRUGS TO AVOID - 2021 UPDATE  Independent French medical journal Prescrire has published its annual update of drugs to avoid. The goal is to make it easier to choose high-quality care, and to prevent disproportionate harm to patients. > Read more

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Read more All the subjects in Prescrire's Spotlight >

• Sitemap |
• Terms of use |
• Contact
• |Top of page